Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 361 of 1,261
  1. US 10940153

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  2. US 10940160

    Biomarkers for predicting responsiveness to decitabine therapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  3. US 10940142

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  4. US 10940133

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    Jazz Pharmaceuticals Ireland Limited · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  5. US 10940109

    Multilayer polymeric matrix based medical devices

    The Regents of the University of Colorado · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  6. US 10940141

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  7. US 10941183

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  8. US 10940188

    Compounds and methods for treatment and prevention of Flavivirus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  9. US 10940211

    Human antibodies to S. aureus hemolysin A toxin

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  10. US 10941140

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  11. US 10941213

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  12. US 10941402

    Chemically modified single-stranded RNA-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  13. US 10941187

    GLP-1, exendin-4, peptide analogs and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  14. US 10941175

    Pyrrolopyrimidine nucleosides and analogs thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  15. CA 3152006

    TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Mar 4, 2021 · Expires Feb 27, 2041

    granted
  16. US 10933022

    Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

    Oramed Ltd. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  17. US 10934363

    Chimeric antigen receptors based on single domain antibodies and methods of use thereof

    LEGEND BIOTECH USA INC. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  18. US 10934550

    Immunotherapy of cancer

    Phio Pharmaceuticals Corp. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  19. US 10934349

    Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  20. US 10934306

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  21. US 10933081

    Myostatin iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  22. US 10934302

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  23. US 10933130

    Vaccines with interleukin-33 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  24. US 10933094

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.